Risks and benefits of phase 1 oncology trials, revisited

N Engl J Med. 2005 Mar 3;352(9):930-2. doi: 10.1056/NEJMe058007.
No abstract available

Publication types

  • Comment
  • Editorial

MeSH terms

  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / adverse effects
  • Clinical Trials, Phase I as Topic* / ethics
  • Dose-Response Relationship, Drug
  • Humans
  • Neoplasms / drug therapy*
  • Risk Assessment

Substances

  • Antineoplastic Agents